72.11.Z - Research and experimental development on biotechnology
20.59.Z - Manufacture of other chemical products not elsewhere classified
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
46.45.Z - Wholesale of perfume and cosmetics
46.46.Z - Wholesale of pharmaceutical goods
62.01.Z - Computer programming activities
62.02.Z - Computer consultancy activities
71.20.B - Other technical testing and analysis
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 0,7 | 0,5 | 0,4 | -17,1 |
EBITDA | 0,7 | 0,5 | 0,4 | -16,8 |
Short time liabilities | 1 | 0 | 0 | 0 |
Equity capital | 0,4 | 0,9 | 1,3 | 45,2 |
Operating profit (EBIT) | 0,7 | 0,5 | 0,4 | -16,8 |
Assets | 1,4 | 0,9 | 1,3 | 45,2 |
Net profit (loss) | 0,7 | 0,5 | 0,4 | -17,1 |
Cash | 1,4 | 0,9 | 1,3 | 45,2 |
Net income from sale | 8,4 | 10 | 12,5 | 25 |
Liabilities and provisions for liabilities | 1 | 0 | 0 | 0 |
Working assets | 1,4 | 0,9 | 1,3 | 45,2 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | 172,4 | 54,6 | 31,1 | -23,5 |
Equity capital to total assets | 29,8 | 100 | 100 | 0 |
Gross profit margin | 8,5 | 5 | 3,3 | -1,7 |
EBITDA Margin | 8,5 | 5 | 3,3 | -1,7 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 43 | 0 | 0 | 0 |
Current financial liquidity indicator | 1.4237626791000366 | 0,8 | ||
Net dept to EBITDA | -1.9487894773483276 | -1.8395761251449585 | -3.210293769836426 | -1,4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane